LOX1.1 Antibody

What is LOX-1 and why is it an important research target?

LOX-1 (Lectin-like Oxidized Low-density Lipoprotein Receptor 1), also known as OLR1 or C-type lectin domain family 8 member A, is a transmembrane scavenger receptor that plays a critical role in cardiovascular disease pathogenesis. LOX-1 is a primary receptor for oxidized LDL (oxLDL) and triggers downstream pathways that contribute to atherosclerosis through endothelial dysfunction, oxLDL uptake, and apoptosis . The receptor has emerged as a promising target for early diagnosis, cardiovascular risk prediction, and potential therapeutic intervention . LOX-1 is expressed in various cell types including endothelial cells, macrophages, vascular smooth muscle cells, cardiomyocytes, and fibroblasts, making it relevant to multiple disease mechanisms .

What is the molecular structure of LOX-1?

LOX-1 is expressed as a type II transmembrane protein containing four distinct domains:

• An extracellular C-terminal lectin domain

• A connecting neck domain

• A single transmembrane domain

• A short N-terminal cytoplasmic tail

The protein forms a homodimer through a disulfide bond between monomers at cysteine 140 residues . There is some inconsistency in the literature regarding LOX-1's molecular weight, with commercial suppliers reporting approximately 37 kDa, while peer-reviewed sources often indicate 45-50 kDa . This discrepancy may be important when validating antibody specificity.

How should researchers select appropriate anti-LOX-1 antibodies for their experiments?

When selecting anti-LOX-1 antibodies, researchers should consider:

• Target epitope: Determine whether you need antibodies against the extracellular domain (ECD) or intracellular domain (ICD) based on your experimental design. Different domains may be accessible in different experimental conditions.

• Validation status: Review literature to confirm antibody specificity. Recent research has identified discrepancies in antibody recognition patterns, with each antibody potentially recognizing different proteins of varying molecular weights (29, 31, 50, or 55 kDa) .

• Application compatibility: Verify the antibody has been validated for your specific application (Western blot, ELISA, immunohistochemistry, etc.) .

• Species reactivity: Ensure compatibility with your experimental model, noting differences between human and murine LOX-1 .

What validation steps are recommended before using a new LOX-1 antibody?

Given the inconsistencies reported in LOX-1 antibody specificity , thorough validation is essential:

• Positive and negative controls: Include OLR1-transfected cells as positive controls and appropriate negative controls in initial experiments .

• Multiple antibody comparison: When possible, use multiple antibodies targeting different LOX-1 epitopes to confirm findings .

• Complementary techniques: Validate protein expression findings with mRNA analysis (e.g., RT-PCR or RNA-seq for OLR1) .

• Molecular weight verification: Compare observed molecular weights with expected values, noting that full-length LOX-1 monomer is approximately 37 kDa, while soluble forms (sLOX-1) may be detected at 22-24 kDa .

How can LOX-1 antibodies be optimized for ELISA detection of soluble LOX-1 (sLOX-1)?

For optimal ELISA detection of sLOX-1:

• Sandwich ELISA design: Establish a sandwich ELISA using a capture antibody targeting one epitope (e.g., Mouse anti-Human LOX-1 antibody, clone DE15-4H4) and a detection antibody targeting a different epitope (e.g., biotinylated Mouse anti-Human LOX-1 antibody, clone DE17-4B9) .

• Sample preparation: Consider potential interfering factors in serum or plasma samples and optimize sample dilution.

• Antibody validation: Verify that your antibodies specifically recognize sLOX-1 by confirming recognition of recombinant sLOX-1 standards.

• Cross-reactivity testing: Test for potential cross-reactivity with other proteins, particularly those with lectin domains.

What experimental approaches can resolve contradictory findings about LOX-1 expression in platelets?

Recent research challenges the previously accepted notion that platelets express LOX-1 . To address these contradictions:

• Multi-antibody approach: Employ multiple well-validated antibodies targeting different LOX-1 domains (both extracellular and intracellular) .

• Protein standards: Include recombinant LOX-1 protein standards (both ECD and ICD fragments) as positive controls in Western blots .

• Transcriptomic validation: Analyze OLR1 mRNA expression using RNA-seq or RT-PCR to confirm protein findings .

• Functional studies: Assess functional responses to oxLDL that would be expected with LOX-1 expression.

• Cellular fractionation: Examine LOX-1 expression in different cellular compartments.

How can LOX-1 antibodies be utilized to study LOX-1-mediated immune signaling?

LOX-1 plays important roles in immune function beyond its classic role in atherosclerosis:

• Dendritic cell targeting: Anti-LOX-1 antibodies can target antigens to dendritic cells, efficiently eliciting antigen-specific IFNγ-producing CD4+ T cell responses .

• B cell interaction studies: LOX-1-expressing dendritic cells interact with IgD+ B cells in the marginal zone. Anti-LOX-1 antibody pre-treatment of DCs promotes B cell proliferation, plasmablast differentiation, and enhanced antibody secretion .

• Cytokine production analysis: Analyze dendritic cell production of BAFF and APRIL following LOX-1 engagement, as these factors promote B cell responses .

• Transcription factor assessment: Evaluate STAT3 and BLIMP1 expression in B cells co-cultured with LOX-1-activated dendritic cells .

What are the methodological considerations for identifying cleavage sites in LOX-1 using antibody-based approaches?

To study proteolytic processing of LOX-1:

• Tagged constructs: Generate LOX-1 constructs with epitope tags at both N- and C-termini (e.g., V5-LOX-1-FLAG) to track both fragments after cleavage .

• Site-directed mutagenesis: Create glycosylation site mutants (e.g., N72A for murine, N73A for human LOX-1) to reduce complexity for mass spectrometric analysis .

• Protease inhibitor studies: Use specific inhibitors to identify proteases responsible for LOX-1 cleavage.

• Immunoprecipitation: Perform sequential immunoprecipitation with different domain-specific antibodies to isolate and characterize cleavage fragments.

• Mass spectrometry: Analyze immunoprecipitated fragments to precisely identify cleavage sites.

What are common pitfalls when using LOX-1 antibodies and how can they be addressed?

Common challenges include:

• Inconsistent molecular weight detection: Different antibodies may recognize proteins of varying molecular weights (29, 31, 37, 50, or 55 kDa) . Solution: Always include appropriate positive controls and multiple antibodies.

• Non-specific binding: Some commercially available antibodies show recognition patterns in negative control cells . Solution: Perform extensive validation and include proper negative controls.

• Low signal in native expression systems: LOX-1 is expressed at low levels under normal physiological conditions but upregulated in pathological states . Solution: Consider using stimulated cells or disease models where LOX-1 is upregulated.

• Interference from glycosylation: Post-translational modifications may affect antibody recognition. Solution: Consider deglycosylation treatments when appropriate.

How can researchers differentiate between membrane-bound LOX-1 and soluble LOX-1 in experimental samples?

To distinguish between membrane-bound and soluble LOX-1:

• Domain-specific antibodies: Use antibodies targeting the extracellular domain to detect both forms, while antibodies against the intracellular domain will detect only membrane-bound LOX-1 .

• Subcellular fractionation: Separate membrane fractions from soluble fractions before Western blotting.

• Size discrimination: Full-length LOX-1 appears at ~37-50 kDa, while soluble forms (sLOX-1) are detected at ~22-24 kDa .

• Media collection: Analyze culture media for secreted sLOX-1, which can be detected only by extracellular domain-specific antibodies.

How can LOX-1 antibodies be utilized in developing therapeutic approaches?

LOX-1 antibodies show potential for therapeutic development:

• Neutralizing antibodies: Develop and test neutralizing antibodies that block oxLDL binding to LOX-1, potentially reducing atherosclerotic progression .

• Targeted drug delivery: Conjugate therapeutic agents to anti-LOX-1 antibodies to target cells expressing high levels of LOX-1 in pathological conditions.

• Dendritic cell modulation: Exploit LOX-1's role in dendritic cell function to develop immunomodulatory approaches, particularly for enhancing Th1 responses .

• Diagnostic applications: Develop assays using anti-LOX-1 antibodies to measure sLOX-1 as a biomarker for cardiovascular disease risk .

What methodological approaches can resolve discrepancies in LOX-1 molecular weight reporting?

To address molecular weight inconsistencies:

• Comprehensive analysis: Compare commercial and academic antibodies side-by-side against recombinant standards of known molecular weight .

• Post-translational modification assessment: Analyze glycosylation patterns which may contribute to observed molecular weight differences.

• Cross-species comparison: Compare human and murine LOX-1 recognition patterns with species-specific antibodies .

• Mass spectrometry validation: Use mass spectrometry to definitively determine the molecular weight of immunoprecipitated LOX-1.

• Denaturation conditions: Test different sample preparation methods as protein folding may affect antibody recognition and apparent molecular weight.